UltraGreen.ai Secures Singapore Approval for Verdye: Boosting AI-Powered Precision Surgery in Asia

Singapore healthcare innovator UltraGreen.ai has obtained regulatory approval for its flagship product Verdye, an indocyanine green injection for fluorescence-guided surgery.

This approval marks a key step in deploying Verdye across oncology, colorectal, reconstructive, and vascular procedures in Southeast Asia.

UltraGreen.ai's Meteoric Growth

Founded as a pioneer in fluorescence technologies, UltraGreen.ai integrates pharmaceuticals, imaging hardware like the IC-Flow system, and AI analytics into a unified surgical platform.

The company recently went public on the Singapore Exchange and secured a $188 million investment led by 65 Equity Partners and Vitruvian Partners.

Prior approvals include Verdye in the Philippines and IC-Flow in 45 markets worldwide, now totaling 41 countries for the dye.

Transforming Surgical Precision

Fluorescence-guided surgery uses Verdye's glow under near-infrared light to reveal blood flow and tissues invisible to the naked eye, slashing complication risks.

For patients, this means fewer post-operative issues in cancer removals or reconstructions, directly improving recovery times and survival rates.

Singapore's stringent regulations position it as a launchpad for ASEAN medtech, amid rising demand for AI-assisted minimally invasive procedures post-pandemic.

Future Outlook and Broader Impact

CEO Ravi Sajwan highlighted Singapore as a reference for regional clinical adoption, fueling partnerships with hospitals.

Industry experts see this accelerating UltraGreen.ai's integrated ecosystem, potentially standardizing surgeries and cutting global healthcare costs by billions.

Ultimately, innovations like Verdye empower everyday surgeons to achieve expert-level precision, making advanced care accessible beyond elite centers.

As Asia's medtech hub grows, this approval underscores why regulatory wins in Singapore signal waves of safer, smarter healthcare worldwide.